title: Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
abstract: In order to achieve the analytical assessment of the manufactured batches of chemotherapy preparations, post-production quality control has been developed. The common use of camptothecin derivatives (i.e. irinotecan (CPT-11) and topotecan (TPT)) as part of protocols in Institut Gustave Roussy (IGR) has led to develop an efficient analytical method that could assess an increasing number of samples with high throughput, good specificity and practicality. Due to the difference of concentration between batches containing irinotecan or topotecan, HPLC and HPTLC both combined with fluorescence detection were investigated. Those two techniques made identity, purity and quantitation assays possible. The chromatographic conditions that were chosen allowed identification of each drug through their rate of flow (Rf), 0.10 and 0.35, or their retention time (tR), 2 and 7 min for topotecan and irinotecan, respectively. A calibration curve was plotted for each molecule and validated by three quality controls (high, medium and low). Coefficients of variation of repeatability (CVr) and intermediate precision (CVi) were determined for both methods. Considering their values and the concentration ranges (from 100 to 500 mg/L for HPTLC and from 0.1 to 1 mg/L for HPLC), it was decided to perform analysis using HPTLC for irinotecan preparations and HPLC for topotecan preparations. These inferences seemed appropriate regarding the number of preparations to be assayed.
authors: Department of Clinical Pharmacy, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France.
authors: Edmond
authors: E
authors: Gravel
authors: Philippe
authors: P
authors: Bourget
authors: Lionel
authors: L
authors: Mercier
authors: Angelo
authors: A
authors: Paci
mesh_terms: D000970:Antineoplastic Agents / Q000032:analysis*; D002138:Calibration; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000032:analysis / Q000138:chemical synthesis* / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002845:Chromatography; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D002855:Chromatography, Thin Layer; D003720:Densitometry; D004345:Drug Industry / Q000379:methods*; D004355:Drug Stability; D000077146:Irinotecan; D008956:Models, Chemical; D004364:Pharmaceutical Preparations / Q000032:analysis; D011786:Quality Control; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013678:Technology, Pharmaceutical; D019772:Topotecan / Q000032:analysis* / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin